Atlas Trials

Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma

Clinical trial NCT05889221 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05889221
Sponsor
Poitiers University Hospital
Status
ACTIVE_NOT_RECRUITING
Phase
Not Applicable
Study type
INTERVENTIONAL
Multiple MyelomaMyeloma MultipleMyeloma
Start date
2023-10-23
Primary completion
2026-03-16
Enrollment
74

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.